TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25266313

Group type: EXPERIMENTAL
Intervention: Resistive warming mattress
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control
Number of subjects: 116
Study: 23185760

Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba Tablet (GBT), 1 tablet each time, 3 times a day for 12 months
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (basic treatment only)
Number of subjects: 113
Study: 19829141

Group type: EXPERIMENTAL
Intervention: Local intracoronary infusion of abciximab through the ClearWayRX System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracoronary infusion of abciximab via the guiding catheter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups receive intravenous infusion of abciximab during the 12‐h period following the procedure
Number of subjects: 0
Study: 17608573

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (160 mJ/pulse at 10 Hz)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ultrasonic scaler treatment
Number of subjects: 25
Study: 16232156

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 49
Study: 12122527

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 11
Study: 11261739

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/die administered at 10.00 PM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/die administered at 8.00 AM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/die administered at 4.00 PM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/die administered at night (10.00 PM)
Number of subjects: 40
Study: 7717566

Group type: EXPERIMENTAL
Intervention: 1 MAC isoflurane
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1 MAC enflurane
Number of subjects: 28
Study: 1961957

Group type: EXPERIMENTAL
Intervention: Propofol induction (2.5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental induction (4-5 mg/kg)
Number of subjects: 40
Study: 7017018

Group type: EXPERIMENTAL
Intervention: Elective appendectomy at the time of transplantation
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Profound lymphocytopenia
Number of subjects: 75
Study: 31735238

Group type: EXPERIMENTAL
Intervention: ProSAAF program
Number of subjects: 346
Study: 27789177

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate mouthwash (n=23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Octenidine-based, chlorhexidine-free mouthwash (n=20)
Number of subjects: 43
Study: 25502610

Group type: EXPERIMENTAL
Intervention: Automated counseling website
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard website
Number of subjects: 97
Study: 24480156

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT) in non-smokers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT) in smokers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resting MBF in smokers
Number of subjects: 20
Study: 22137859

Group type: EXPERIMENTAL
Intervention: Capillary blood sampling using the Chempaq Express Blood Counter (point-of-care device)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Traditional venous blood sampling
Number of subjects: 85
Study: 20310020

Group type: EXPERIMENTAL
Intervention: 1 g mesalamine suppository once daily
Number of subjects: 354

Group type: COMPARATOR
Intervention: 0.5 g mesalamine suppository thrice daily
Number of subjects: 354
Study: 17903638

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 8695

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 8695
Study: 15848517

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) introduced instead of azathioprine (AZA) in group 1 (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Azathioprine (AZA) maintained in group 2 (n = 18)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (MMF and AZA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Conversion of AZA to MMF
Number of subjects: 35
Study: 12150347

Group type: EXPERIMENTAL
Intervention: 10% triacylglycerol emulsion (500 ml, 450 Kcal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20% triacylglycerol emulsion (500 ml, 900 Kcal)
Number of subjects: 30
Study: 10379369

Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam-fentanyl
Number of subjects: 30
Study: 7597305

Group type: EXPERIMENTAL
Intervention: Immunotherapy with IFN alpha and high-dose IL-2
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chemotherapy with dacarbacine (DTIC) followed by IFN-alpha
Number of subjects: 45

Group type: COMPARATOR
Intervention: Single dose of DTIC or cisplatinum (CDDP) followed by IFN-alpha/IL-2
Number of subjects: 45
Study: 1972927

Group type: EXPERIMENTAL
Intervention: 10 mg astemizole
Number of subjects: 105

Group type: COMPARATOR
Intervention: 10 mg cetirizine
Number of subjects: 105
Study: 6975997

Group type: EXPERIMENTAL
Intervention: Phenprocoumon (oral anticoagulant therapy)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no oral anticoagulant therapy)
Number of subjects: 174
Study: 30685831

Group type: EXPERIMENTAL
Intervention: Information-based hospital-family integration continuous care model (WeChat, blog, QQ, telephone, etc.)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Routine standard of care
Number of subjects: 155
Study: 31856909

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) plus Denosumab (120 mg every 2 weeks, following nivolumab)
Number of subjects: 30
Study: 28663610

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% lignocaine
Number of subjects: 100
Study: 25895016

Group type: EXPERIMENTAL
Intervention: CDS (computerized clinical decision support)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: CDS + coaching
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: CDS
Number of subjects: 549

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 549
Study: 23559221

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Belief of consuming glucose
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 17601194

Group type: EXPERIMENTAL
Intervention: Wilmington robotic exoskeleton (WREX)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Without WREX
Number of subjects: 17
Study: 15082280

Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg intravenously after induction, maintained with 0.5 mg/kg per hour)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no aminophylline)
Number of subjects: 30
Study: 10921758

Group type: EXPERIMENTAL
Intervention: HFA‐BDP 400 microg day(‐1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: CFC‐BDP 1000 microg day(‐1)
Number of subjects: 150
Study: 8957982

Group type: EXPERIMENTAL
Intervention: Sodium citrate 0.3 mol litre‐1 (antacid)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium citrate dehydrate (100 mg ml‐1) with citric acid monohydrate (66 mg ml‐1) (buffer)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no gastric solution)
Number of subjects: 20
Study: 7687142

Group type: EXPERIMENTAL
Intervention: Low molecular weight hydroxyethyl starch solution (LMW‐HES) (6% HES; mean molecular weight 200,000 Da, molar substitution 0.5)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20% albumin (HA)
Number of subjects: 30
Study: 3698726

Group type: EXPERIMENTAL
Intervention: Single-dose mezlocillin (5 grams preoperative)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Multiple-dose mezlocillin (3 doses of 2 grams perioperative)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 30414284

Group type: EXPERIMENTAL
Intervention: OIT with pasteurized egg white (PEW) - daily 3.3 g proteins (AG)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: OIT with pasteurized egg white (PEW) - every two days (BG)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: OIT with pasteurized egg white (PEW)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Egg-free diet (CG)
Number of subjects: 101
Study: 27314148

Group type: EXPERIMENTAL
Intervention: Lidocaine heated to body temperature (37°C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lidocaine at room temperature (21°C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cold lidocaine (8°C)
Number of subjects: 36
Study: 25823635

Group type: EXPERIMENTAL
Intervention: Cannabis cessation intervention
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Exploratory analysis of cannabis use
Number of subjects: 112
Study: 22882698

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m²) plus cisplatin (75 mg/m²)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² on days 1 and 8) plus cisplatin (75 mg/m²)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Pemetrexed/cisplatin
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Pemetrexed-platinum (meta-analysis)
Number of subjects: 251
Study: 21129053

Group type: EXPERIMENTAL
Intervention: Imagery rehearsal
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Exposure
Number of subjects: 198

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 198

Group type: COMPARATOR
Intervention: Nightmare recording group
Number of subjects: 198
Study: 19644646

Group type: EXPERIMENTAL
Intervention: ProLoop plug (Atrium)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Perfix plug (Bard)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Lichtenstein tension free mesh repair (LTFM)
Number of subjects: 295
Study: 16675380

Group type: EXPERIMENTAL
Intervention: Educational poster intervention during the poster month
Number of subjects: 720

Group type: COMPARATOR
Intervention: Historical control periods (3 months prior)
Number of subjects: 720
Study: 15260907

Group type: EXPERIMENTAL
Intervention: 200 mg of 5-hydroxytryptophan (5-HTP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 200 mg of 5-hydroxytryptophan (5-HTP) in females
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 200 mg of 5-hydroxytryptophan (5-HTP) in males
Number of subjects: 32
Study: 11416734

Group type: EXPERIMENTAL
Intervention: Structured treatment interruptions (STI) in 12 patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-interrupters (continued HAART) in 14 patients
Number of subjects: 26
Study: 9316536

Group type: COMPARATOR
Intervention: VVI pacing at the same average rate as during intrinsically conducted AF (102 ± 22 beats/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Irregular sequence of RR intervals
Number of subjects: 16
Study: 8361472

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day added to immuno-chemotherapy (Tegaful, Mitomycin, Krestin, OK-432)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-Tamoxifen group (14 cases)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tamoxifen in cases with estrogen receptor
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tamoxifen in cases without estrogen receptor
Number of subjects: 27
Study: 3518464

Group type: COMPARATOR
Intervention: Timolol 0.25% and 0.5%
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 38
Study: 29433275

Group type: EXPERIMENTAL
Intervention: Low voltage electrical stimulation (LVES) for 30s at 7min post-mortem
Number of subjects: 26
Study: 26967206

Group type: EXPERIMENTAL
Intervention: ACC-001 + QS-21
Number of subjects: 245

Group type: COMPARATOR
Intervention: ACC-001
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 24764496

Group type: EXPERIMENTAL
Intervention: Partners in Dementia Care (PDC)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 508
Study: 21760633

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 250

Group type: COMPARATOR
Intervention: Treatment preference
Number of subjects: 250
Study: 20060863

Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate (HP/LC) breakfast
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low protein/high carbohydrate (LP/HC) breakfast
Number of subjects: 21
Study: 17902001

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (‐TRP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (+TRP)
Number of subjects: 16
Study: 15644831

Group type: EXPERIMENTAL
Intervention: Asthma intervention
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group (undiagnosed)
Number of subjects: 299
Study: 15228241

Group type: EXPERIMENTAL
Intervention: ITNs and SP
Number of subjects: 752

Group type: COMPARATOR
Intervention: ITNs and placebo SP
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: SP alone
Number of subjects: 752

Group type: COMPARATOR
Intervention: placebo SP
Number of subjects: 752
Study: 10551571

Group type: COMPARATOR
Intervention: Sham TENS (no stimulation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-frequency (2-Hz) TENS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-frequency (100-Hz) TENS
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mixed-frequency (2- and 100-Hz) TENS
Number of subjects: 100
Study: 8896540

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (Oka/SB Bio)
Number of subjects: 1400
Study: 1803786

Group type: EXPERIMENTAL
Intervention: Lanoxin 0.125 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lanoxicaps 0.1 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lanoxin 0.25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lanoxicaps 0.2 mg
Number of subjects: 20
Study: 6340512

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups (with cystoid macular edema)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups (without cystoid macular edema)
Number of subjects: 124
Study: 31973959

Group type: EXPERIMENTAL
Intervention: Video Glasses (VG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Portable Multimedia Player (PMP)
Number of subjects: 0
Study: 30414225

Group type: EXPERIMENTAL
Intervention: Probiotic capsules
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 240
Study: 27583797

Group type: EXPERIMENTAL
Intervention: 18 mW/cm ultraviolet A irradiation for 120 seconds
Number of subjects: 23

Group type: COMPARATOR
Intervention: 18 mW/cm ultraviolet A irradiation for 180 seconds
Number of subjects: 23
Study: 26037245

Group type: EXPERIMENTAL
Intervention: Doxazosin (titrated to 16 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24245604

Group type: EXPERIMENTAL
Intervention: Secure text message visualisation tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral text message visualisation tasks
Number of subjects: 0
Study: 21725919

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS)
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Adjustment for other known and potential risk factors
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Adjustment for creatinine
Number of subjects: 1706
Study: 19214951

Group type: EXPERIMENTAL
Intervention: BCG therapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: PDT with Photofrin
Number of subjects: 124
Study: 17541103

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 2177

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 2177
Study: 15165530

Group type: EXPERIMENTAL
Intervention: autoCPAP
Number of subjects: 22

Group type: COMPARATOR
Intervention: fixed CPAP
Number of subjects: 22
Study: 11753021

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study: 9612619

Group type: EXPERIMENTAL
Intervention: Adjuvant 5-fluorouracil based chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 0
Study: 7751115

Group type: EXPERIMENTAL
Intervention: Titanium-reinforced membrane and osseointegrated implants
Number of subjects: 5
Study: 2661788

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.1 mg/kg four times a day, 1/2 hour before feeding for 1 week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 30
Study: 29931294

Group type: EXPERIMENTAL
Intervention: Flapless piezocision‐assisted corticotomy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional orthodontic treatment (Control)
Number of subjects: 36
Study: 28288057

Group type: EXPERIMENTAL
Intervention: Mesorectal excision with lateral lymph node dissection (ME with LLND)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Mesorectal excision alone (ME alone)
Number of subjects: 701
Study: 25713025

Group type: EXPERIMENTAL
Intervention: Regular aspirin use (moderate versus nonregular use)
Number of subjects: 1819

Group type: COMPARATOR
Intervention: Ibuprofen use
Number of subjects: 1819
Study: 23414206

Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Cancer Recovery (MBCR) program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waiting for the next available group (Control)
Number of subjects: 64
Study: 21504893

Group type: EXPERIMENTAL
Intervention: SNP rs9350 in Exonuclease-1 (EXO1)
Number of subjects: 2836

Group type: EXPERIMENTAL
Intervention: SNP rs17503908 in ataxia telangiectasia mutated (ATM)
Number of subjects: 2836
Study: 18355138

Group type: EXPERIMENTAL
Intervention: Prophylactic insertion of Double-J stents for 4 weeks
Number of subjects: 195

Group type: COMPARATOR
Intervention: Stentless (control group)
Number of subjects: 195
Study: 16507028

Group type: EXPERIMENTAL
Intervention: Group treatment programme for depression
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 14552511

Group type: EXPERIMENTAL
Intervention: Documentary about schizophrenia
Number of subjects: 163

Group type: COMPARATOR
Intervention: No documentary film
Number of subjects: 163

Group type: COMPARATOR
Intervention: Documentary about polar bears
Number of subjects: 163

Group type: COMPARATOR
Intervention: Documentary about fears of being overweight
Number of subjects: 163
Study: 10945511

Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (0.1 mg/d)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (0.05 mg/d)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (0.0375 mg/d)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (0.025 mg/d)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Estradiol matrix transdermal system (all doses)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 8837408

Group type: EXPERIMENTAL
Intervention: Subjects attending to the predictive aspect of FOK definitions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subjects assessing what they believed they knew
Number of subjects: 0
Study: 1308130

Group type: EXPERIMENTAL
Intervention: Intensive control with a step-up regimen including insulin alone or insulin/glipizide combinations
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard therapy group with insulin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both groups (intensive and standard control)
Number of subjects: 151
Study: 6363659

Group type: EXPERIMENTAL
Intervention: Antenatal dexamethasone administration
Number of subjects: 739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study: 3086948

Group type: EXPERIMENTAL
Intervention: Mepivacaine carbonate (1% solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mepivacaine hydrochloride
Number of subjects: 30
Study: 29266879

Group type: EXPERIMENTAL
Intervention: Celecoxib (100-200 mg twice daily)
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Ibuprofen (600-800 mg 3 times daily)
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Naproxen (375-500 mg twice daily)
Number of subjects: 24081
Study: 28915919

Group type: EXPERIMENTAL
Intervention: Project LifeSkills intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet and nutrition time- and attention-matched control
Number of subjects: 0
Study: 25936817

Group type: EXPERIMENTAL
Intervention: Pretreatment FDG-PET (PET arm)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (no pretreatment FDG-PET)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Overall survival and disease-free survival (both arms)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Freedom from extrapelvic metastasis (both arms)
Number of subjects: 129
Study: 23715246

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation 4 times a day for 6 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20656831

Group type: EXPERIMENTAL
Intervention: Single reading with CAD
Number of subjects: 28204

Group type: EXPERIMENTAL
Intervention: Double reading
Number of subjects: 28204

Group type: EXPERIMENTAL
Intervention: CAD
Number of subjects: 28204
Study: 18379395

Group type: EXPERIMENTAL
Intervention: Waterbed (Akva)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Body-conforming foam mattress (Tempur)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Hard mattress (Innovation Futon)
Number of subjects: 141
Study: 16685087

Group type: EXPERIMENTAL
Intervention: Biodegradable interference screw (PLLA group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Metal interference screw (metal group)
Number of subjects: 77
Study: 12580983

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 50 mg
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 11081541

Group type: EXPERIMENTAL
Intervention: Yoga practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow breathing rate during yoga
Number of subjects: 0
Study: 8781000

Group type: EXPERIMENTAL
Intervention: Computer-tailored nutrition intervention
Number of subjects: 347

Group type: COMPARATOR
Intervention: General nutrition information
Number of subjects: 347